Table 2.

Anticancer and Wnt/β-catenin signaling data of mefenamic amides 2a–2o.

Cpd	Cell line - CC50 (µM)			Wnt/β-catenin
	HT29	PC3	MDA-MB-231	% Control (100 µM)	% Control (10 µM)
2a	5.93 ± 0.95	17.69 ± 2.91	17.35 ± 9.25	8.15 ± 1.73	64.46 ± 0.36
2b	31.50 ± 3.63	>50	25.83 ± 3.97	42.15 ± 4.53	73.55 ± 3.55
2c	12.06 ± 1.21	33.91 ± 4.86	10.78 ± 2.65	2.25 ± 0.70	59.64 ± 7.64
2d	>50	>50	>50	47.19 ± 6.36	ND
2e	>50	>50	>50	255.95 ± 59.07	ND
2f	11.52 ± 0.88	20.55 ± 2.39	19.21 ± 2.08	N/A	163.22 ± 37.56
2g	15.14 ± 0.41	33.82 ± 4.77	27.44 ± 1.64	196.32 ± 9.61	ND
2h	19.68 ± 0.84	>50	>50	178.13 ± 9.46	ND
2i	39.45 ± 2.33	>50	>50	189.74 ± 10.96	ND
2j	28.55 ± 0.88	>50	>50	179.79 ± 15.34	ND
2k	12.98 ± 0.39	29.06 ± 2.98	30.81 ± 1.73	18.84 ± 2.24	ND
2l	6.08 ± 0.38	10.41 ± 1.29	11.32 ± 1.35	N/A	132.88 ± 10.51
2m	8.27 ± 0.45	9.82 ± 1.11	13.20 ± 0.43	N/A	174.42 ± 37.71
2n	19.51 ± 0.94	>50	>50	144.22 ± 7.82	ND
2o	8.73 ± 0.61	20.45 ± 2.55	>50	100.10 ± 8.28	ND

N/A not available due to cell toxicity at this concentration, ND not done